11:24 AM EDT, 06/16/2025 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Monday that it resubmitted its new drug application for Cardamyst nasal spray to the US Food and Drug Administration for the treatment of acute episodes of paroxysmal supraventricular tachycardia.

The company submitted a response to the FDA's complete response letter, and the regulator has thirty days to accept and determine the review time, which is expected to be within two or six months.

The response was submitted after a type A meeting with the FDA, according to Milestone.

Shares of the company were up 1.2% in recent trading.

Price: 1.67, Change: +0.02, Percent Change: +1.21